Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors

ACS Med Chem Lett. 2013 Oct 15;4(12):1193-7. doi: 10.1021/ml400307j.

Matthew T Burger ¹, Wooseok Han ¹, Jiong Lan ¹, Gisele Nishiguchi ¹, Cornelia Bellamacina ¹, Mika Lindval ¹, Gordana Atallah ¹, Yu Ding ¹, Michelle Mathur ¹, Chris McBride ¹, Elizabeth L Beans ¹, Kristine Muller ¹, Victoriano Tamez ¹, Yanchen Zhang ¹, Kay Huh ¹, Paul Feucht ², Tatiana Zavorotinskaya ², Yumin Dai ², Jocelyn Holash ², Joseph Castillo ², John Langowski ², Yingyun Wang ², Min Y Chen ², Pablo D Garcia ²

Affiliations

1 Global Discovery Chemistry/Oncology & Exploratory Chemistry, Novartis Institutes for Biomedical Research , 4560 Horton Street, Emeryville, California 94608, United States.
2 Oncology Research, Novartis Institutes for Biomedical Research , 4560 Horton Street, Emeryville, California 94608, United States.

PMID: 24900629 DOI: 10.1021/ml400307j

Abstract

Proviral insertion of Moloney virus (Pim) 1, 2, and 3 kinases are serine/threonine kinases that normally function in survival and proliferation of hematopoietic cells. As high expression of PIM1, 2, and 3 is frequently observed in many human malignancies, including multiple myeloma, non-Hodgkins lymphoma, and myeloid leukemias, there is interest in determining whether selective Pim inhibition can improve outcomes of these human cancers. Herein, we describe our efforts toward this goal. The structure guided optimization of a singleton high throughput screening hit in which the potency against all three Pim isoforms was increased >10,000-fold to yield compounds with pan Pim K is < 10 pM, nanomolar cellular potency, and in vivo activity in an acute myeloid leukemia Pim-dependent tumor model is described.

Keywords

Pim1 kinase inhibitor; Pim2 kinase inhibitor; Pim3 kinase inhibitor; Proviral insetion site in Moloney murine leukemia virus kinases inhibitors; pan-Pim kinase inhibitors.

Name
Email *

	Sorry, but the email address you supplied was invalid.